Physician profile
Donna E Sweet
NPI 1982679478
$185,289.53
in general payments reported to CMS, 2019-2025
23 companies · $8,380 in 2025
The $8,380 reported for 2025 was more than what 98% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $130K · 2020: $16K · 2021: $5,937 · 2022: $7,153 · 2023: $8,288 · 2024: $9,185 · 2025: $8,380.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $18K · Food and Beverage: $4,219 · Travel and Lodging: $4,134.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $17,500.00 |
| Food and Beverage | $4,218.97 |
| Travel and Lodging | $4,134.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $79,102.32 | 2019-2025 | Dovato, Rukobia, Cabenuva |
| Gilead Sciences, INC. | $70,375.32 | 2019-2025 | Biktarvy, Yeztugo |
| Janssen Products, LP | $16,856.62 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $15,461.12 | 2019-2025 | Delstrigo, Gardasil, Gardasil 9 |
| Theratechnologies INC. | $2,000.00 | 2021 | |
| Glaxosmithkline, LLC. | $1,066.37 | 2019 | |
| Janssen Biotech, INC. | $81.84 | 2019-2023 | Symtuza |
| Pfizer INC. | $41.16 | 2024 | |
| Dexcom, INC. | $30.40 | 2025 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $28.48 | 2021 | |
| Abbvie INC. | $28.31 | 2022-2024 | |
| Janssen Scientific Affairs, LLC | $27.12 | 2019 | |
| Abbott Laboratories | $24.07 | 2025 | Freestyle Libre 3 |
| Axsome Therapeutics, INC. | $21.89 | 2025 | Auvelity |
| Lundbeck LLC | $21.38 | 2025 | Rexulti |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Napo Pharmaceuticals INC | $19.53 | 2019 | |
| Sanofi Pasteur INC. | $16.76 | 2019 | |
| Verity Pharmaceuticals INC. | $16.19 | 2025 | Tlando |
| Emd Serono, INC. | $14.87 | 2019 | |
| Bayer Healthcare Pharmaceuticals INC. | $14.67 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $14.14 | 2025 | Caplyta |
| Lilly USA, LLC | $13.89 | 2023 | Mounjaro |
| Sunovion Pharmaceuticals INC. | $13.08 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Donna Sweet listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.